(Q43570282)

24 November 2017

title

Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors (English)

1 reference

24 November 2017

1 reference

1 reference

3

1 reference

24 November 2017

Akhlaghi F

1

1 reference

24 November 2017

Keogh AM

series ordinal

2

1 reference

24 November 2017

Kaan A

series ordinal

4

1 reference

24 November 2017

publication date

1 April 2001

1 reference

The Journal of Heart and Lung Transplantation

24 November 2017

published in

1 reference

24 November 2017

volume

20

1 reference

24 November 2017

issue

4

1 reference

24 November 2017

page(s)

431-438

1 reference

Cyclosporin clinical pharmacokinetics

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

Diltiazem-cyclosporin pharmacokinetic interaction--dose-response relationship

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

Ketoconazole to reduce the need for cyclosporine after cardiac transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

First-pass metabolism of cyclosporin by the gut

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

Cyclosporin metabolism by human gastrointestinal mucosal microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine*

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8)

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900234-5

7 January 2021

10.1016/S1053-2498(00)00234-5

Identifiers

DOI

1 reference

24 November 2017

1 reference